CD274 and non-small cell lung carcinoma: However, when evaluating a subgroup where only NSCLC patients with PD-L1 TPS ≥ 1% and first-line ICB were included, the add-on VA was associated with a reduction in the adjusted hazard of death (56%) compared to the general cohort (40%) as well.